Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Abeona Therapeutics (ABEO) Gross Margin (2020 - 2025)

Abeona Therapeutics (ABEO) has 8 years of Gross Margin data on record, last reported at 75.0% in Q2 2025.

  • For Q2 2025, Gross Margin changed N/A year-over-year to 75.0%; the TTM value through Jun 2025 reached 548.75%, changed N/A, while the annual FY2023 figure was 54.14%, 1403.0% down from the prior year.
  • Gross Margin reached 75.0% in Q2 2025 per ABEO's latest filing, up from 55.0% in the prior quarter.
  • Across five years, Gross Margin topped out at 75.0% in Q2 2025 and bottomed at 47.06% in Q4 2022.
  • Average Gross Margin over 3 years is 36.99%, with a median of 60.0% recorded in 2022.
  • The widest YoY moves for Gross Margin: up -1000bps in 2023, down -1000bps in 2023.
  • A 3-year view of Gross Margin shows it stood at 47.06% in 2022, then soared by 217bps to 55.0% in 2023, then skyrocketed by 36bps to 75.0% in 2025.
  • Per Business Quant database, its latest 3 readings for Gross Margin were 75.0% in Q2 2025, 55.0% in Q2 2023, and 47.06% in Q4 2022.